Jenna L Carter
Overview
Explore the profile of Jenna L Carter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carter J, Su Y, Al-Antary E, Zhao J, Qiao X, Wang G, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):10.
PMID: 39780285
Background: Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy....
2.
Su Y, Carter J, Li X, Fukuda Y, Gray A, Lynch J, et al.
Cancer Res
. 2024 Jan;
84(7):1084-1100.
PMID: 38266099
Significance: In AML cells, ONC213 suppresses αKGDH, which induces a unique mitochondrial stress response, and reduces MCL1 to decrease oxidative phosphorylation and elicit potent antileukemia activity. See related commentary by...
3.
Hurrish K, Su Y, Patel S, Ramage C, Zhao J, Temby B, et al.
Biochem Pharmacol
. 2023 Dec;
220:115981.
PMID: 38081370
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of...
4.
Carter J, Su Y, Qiao X, Zhao J, Wang G, Howard M, et al.
Biochem Pharmacol
. 2023 Aug;
216:115759.
PMID: 37604291
The combination of venetoclax (VEN) and azacitidine (AZA) has become the standard of care for acute myeloid leukemia (AML) patients who are ≥ 75 years or unfit for intensive chemotherapy....
5.
Hurrish K, Su Y, Patel S, Ramage C, Carter J, Edwards H, et al.
Res Sq
. 2023 May;
PMID: 37162954
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of...
6.
Carter J, Hege K, Yang J, Kalpage H, Su Y, Edwards H, et al.
Signal Transduct Target Ther
. 2020 Dec;
5(1):288.
PMID: 33335095
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and the second most common form of acute leukemia in children. Despite this, very little improvement...
7.
Carter J, Hege K, Kalpage H, Edwards H, Huttemann M, Taub J, et al.
Biochem Pharmacol
. 2020 Oct;
182:114253.
PMID: 33011159
Acute myeloid leukemia (AML) is a heterogeneous disease with variable presentation, molecular phenotype, and cytogenetic abnormalities and has seen very little improvement in patient survival over the last few decades....
8.
Read G, Miura N, Carter J, Kines K, Yamamoto K, Devasahayam N, et al.
Colloids Surf B Biointerfaces
. 2018 Jul;
171:197-204.
PMID: 30031304
The purpose of this study is to demonstrate calcium alginate hydrogels as a system for in vitro radiobiological and metabolic studies of cancer cells. Previous studies have established calcium alginate...
9.
Carvajal-Yepes M, Sporer K, Carter J, Colvin C, Coussens P
Hum Vaccin Immunother
. 2015 Jun;
11(9):2296-304.
PMID: 26090991
Influenza is one of the most important infectious diseases in humans. The best way to prevent severe illness caused by influenza infection is vaccination. Cell culture-derived influenza vaccines are being...